NEOD 001

Drug Profile

NEOD 001

Alternative Names: NEOD001

Latest Information Update: 10 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Neotope Biosciences; Onclave Therapeutics
  • Developer Prothena
  • Class Monoclonal antibodies
  • Mechanism of Action Amyloid fibril protein AL inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Amyloid light-chain amyloidosis

Most Recent Events

  • 08 Aug 2017 Prothena completes enrolment in the phase IIb PRONTO trial for Amyloid light chain amyloidosis in USA, Australia, Austria, Germany, France, Israel, Italy, Spain and United Kingdom
  • 08 Aug 2017 Prothena completes enrolment in the phase III VITAL trial for Amyloid light chain amyloidosis in USA, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Greece, Israel, Italy, Netherlands, Poland, Spain and United kingdom
  • 05 Jul 2017 Tufts Medical Center initiates enrolment in the phase IIb RAIN trial for Amyloid light chain amyloidosis in USA (NCT03168906)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top